Health TrialsbyHealthPanel

A Randomized Non-Inferiority Study of Mepi™ Press 2 vs UrgoK2® for Compression Therapy in Venous Leg Ulcers

ConditionsVenous Leg Ulcer (VLU)Compression Bandages
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMolnlycke Health Care AB

About this trial

Venous leg ulcers (VLUs) account for approximately 70% of all lower limb ulcers and affect an estimated 0.032% to 1% of the population in Western countries, corresponding to approximately 265,000 to 650,000 individuals in France. Effective management of VLUs is essential to reduce patient burden and associated healthcare costs. Compression therapy is the cornerstone of VLU treatment , as it improves venous return, reduces oedema, and promotes wound healing. Multilayer compression bandage systems, including two-layer systems, are considered the gold standard, and in France, they are recommended as first-line treatment for VLUs.

The goal of this clinical trial is to evaluate whether the Mepi™ Press 2 compression system is non-inferior to UrgoK2® in the treatment of venous leg ulcers in adult patients.

The main question it aims to answer is:

-Is Mepi™ Press 2 non-inferior to UrgoK2® in terms of the proportion of completely healed VLUs within 12 weeks?

Researchers will compare Mepi™ Press 2 with UrgoK2® to determine whether similar clinical efficacy, performance, and safety can be achieved.

Participants are adult patients with venous leg ulcers of less than 24 months duration requiring treatment with a two-layer compression bandage system. The study is multicenter, involving approximately 25 sites in France, and plans to enroll 386 participants.

Participants will:

* Receive compression therapy with either Mepi™ Press 2 or UrgoK2® in accordance with standard of care * Receive an appropriate primary wound dressing prior to compression * Attend up to five study visits over a period of up to 12 weeks (or until wound healing, whichever occurs first) * Be assessed for wound healing, safety, and device performance throughout the study

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients ≥ 18 years.

Stage C6 venous leg ulcer diagnosed less than 24 months ago.

2cm² ≤ VLU surface area ≤ 40cm².

ABPI equal or higher than 0.8 and equal or lower than 1.3.

Disqualifiers

Any contraindication to investigational or comparator medical devices mentioned in their respective IFUs.

Planned endovenous treatment or surgical venous stripping / exeresis within 8 weeks before planned inclusion date, or before end of participation to the study.

Treatment with chemotherapy or antineoplastic agent within the last 6 months.

Active wound infection or wound infection treatment within the past 4 weeks before inclusion or current use of silver dressings.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Compression bandage system (Mepi™ Press 2)

    Device

    A two-layer compression system consisting of a padded bandage and a cohesive short-stretch bandage with visual indicator. Provides therapeutic compression to support venous leg ulcer management. Applied with an appropriate primary wound dressing and changed as clinically indicated.

  • Compression bandage system (UrgoK2®)

    Device

    A two-layer compression system composed of a short-stretch bandage and a cohesive long-stretch bandage designed to achieve therapeutic compression (\~40 mmHg). Used for venous leg ulcer management with an appropriate primary wound dressing.

  • Wound Dressing Material

    Device

    Appropriate primary wound dressing applied prior to compression therapy according to standard of care.

Treatment groups

386 Participants
are divided into 2 treatment groups
Group A: Mepi™ Press 2- two-layer compression bandageExperimental treatment 2 interventions
Group B: UrgoK2® - multicomponent, compression systemActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

Percentage of patients with complete healing of their VLU

Healing assessment is performed by the site investigator through clinical examination of the wound at the investigational site, during each of the follow-up visits.

Time frame
From enrollment to the end of treatment at 12 weeks, Visit 1(Day 0 + 2 weeks ± 1 day), Visit 2 (D0 + 4 weeks ± 3 days), Visit 3 (D0+ 8 weeks ± 4 days), Visit 4 (D0 + 12 weeks ± 4 day)s

Secondary outcomes

1

Compare reduction of VLU wound area (absolute and relative).

Absolute and percentage VLU wound surface area reduction compared to baseline at all follow-up visits .

Time frame
From enrollment to the end of treatment at 12 weeks, Visit 1(Day 0 + 2 weeks ± 1 day), Visit 2 (D0 + 4 weeks ± 3 days), Visit 3 (D0+ 8 weeks ± 4 days), Visit 4 (D0 + 12 weeks ± 4 day)s
2

Compare proportions of participants reaching 40% wound area reduction at 4 weeks

Proportion of participants reaching ≥40% relative wound area reduction (RWAR) at 4 weeks

Time frame
From enrollment to the follow-up visit at 4 weeks, Visit 1(Day 0 + 2 weeks ± 1 day), Visit 2 (D0 + 4 weeks ± 3 days)
3

Compare time to complete wound healing

Time to wound healed in each cohort, for patients with healed wound at termination.

Time frame
From enrollment to the end of treatment at 12 weeks, Visit 1(Day 0 + 2 weeks ± 1 day), Visit 2 (D0 + 4 weeks ± 3 days), Visit 3 (D0+ 8 weeks ± 4 days), Visit 4 (D0 + 12 weeks ± 4 day)s
4

Compare quality-of-life during treatment and up to 12 weeks.

Quality of Life assessed with Wound-QoL-17 tool at each visit and change compared to baseline.

Time frame
From enrollment to the end of treatment at 12 weeks, Visit 0 (D0) , Visit 1 (D0 + 2 weeks ± 1 day) ,Visit 2 (D0 + 4 weeks ± 3 days), Visit 3 (D0 + 8 weeks ± 4 days), Visit 4 (D0 + 12 weeks ± 4 day)s

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Molnlycke Health Care AB

Lead sponsor

Euraxi Pharma

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: